Abstract
In mammals, glucocorticoid actions appear to have evolved to maintain and enhance energy stores to be used for life-saving gluconeogenesis. They act on the brain to stimulate search behaviors, palatable feeding and emotionally relevant memories, and they act on the body to mobilize stored peripheral energy and direct it to central depots that serve the substrate needs of the liver. Our work in rats shows that searching and intake of palatable foods (sucrose, saccharin and lard) are stimulated by corticosterone in a dose-related fashion. Adrenalectomized rats gain weight poorly, have low fat content, increased sympathetic neural and hypothalamo-pituitary-adrenal outflow, and altered behaviors. Replacement with corticosterone reverses these effects. Surprisingly, when such rats are provided with 30% sucrose to drink, in addition to saline, all of the usual effects of adrenalectomy are corrected without corticosterone. We hypothesize that there is a metabolic feedback system that decreases stress-responsiveness. Although we have not yet identified the signal associated with sucrose drinking, the weight of mesenteric fat correlates inversely with hypothalamic corticotropin-releasing factor (CRF). When rats eat lard and sucrose ad libitum, fat stores increase and CRF, ACTH and corticosterone responses are reduced. During stress, chow intake decreases but intake of lard and sucrose does not. Our current working model suggests that palatability signals and neural signals from fat stores act on brain to reduce activity in the central stress response system. Correlative results from a clinical study support the powerful role of small changes in glucocorticoids in type 2 diabetes.
Keywords: Corticotropin-releasing factor (CRF), type 2 diabetes, abdominal fat, sugar, fat
Current Alzheimer Research
Title: Glucocorticoids, the Etiology of Obesity and the Metabolic Syndrome
Volume: 4 Issue: 2
Author(s): Mary F. Dallman, Susan F. Akana, Norman C. Pecoraro, James P. Warne, Susanne E. la Fleur and Michelle T. Foster
Affiliation:
Keywords: Corticotropin-releasing factor (CRF), type 2 diabetes, abdominal fat, sugar, fat
Abstract: In mammals, glucocorticoid actions appear to have evolved to maintain and enhance energy stores to be used for life-saving gluconeogenesis. They act on the brain to stimulate search behaviors, palatable feeding and emotionally relevant memories, and they act on the body to mobilize stored peripheral energy and direct it to central depots that serve the substrate needs of the liver. Our work in rats shows that searching and intake of palatable foods (sucrose, saccharin and lard) are stimulated by corticosterone in a dose-related fashion. Adrenalectomized rats gain weight poorly, have low fat content, increased sympathetic neural and hypothalamo-pituitary-adrenal outflow, and altered behaviors. Replacement with corticosterone reverses these effects. Surprisingly, when such rats are provided with 30% sucrose to drink, in addition to saline, all of the usual effects of adrenalectomy are corrected without corticosterone. We hypothesize that there is a metabolic feedback system that decreases stress-responsiveness. Although we have not yet identified the signal associated with sucrose drinking, the weight of mesenteric fat correlates inversely with hypothalamic corticotropin-releasing factor (CRF). When rats eat lard and sucrose ad libitum, fat stores increase and CRF, ACTH and corticosterone responses are reduced. During stress, chow intake decreases but intake of lard and sucrose does not. Our current working model suggests that palatability signals and neural signals from fat stores act on brain to reduce activity in the central stress response system. Correlative results from a clinical study support the powerful role of small changes in glucocorticoids in type 2 diabetes.
Export Options
About this article
Cite this article as:
Dallman F. Mary, Akana F. Susan, Pecoraro C. Norman, Warne P. James, la Fleur E. Susanne and Foster T. Michelle, Glucocorticoids, the Etiology of Obesity and the Metabolic Syndrome, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362236
DOI https://dx.doi.org/10.2174/156720507780362236 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia
Current HIV Research In Vitro and In Vivo Metabolism of a Gamma-Secretase Inhibitor BMS-299897 and Generation of Active Metabolites in Milligram Quantities with a Microbial Bioreactor
Current Drug Metabolism Subject Index to Volume 3
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Allocentric to Egocentric Spatial Switching: Impairment in aMCI and Alzheimer's Disease Patients?
Current Alzheimer Research Gliogenesis and Glial Pathology in Depression
CNS & Neurological Disorders - Drug Targets Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets Small Molecule Fluorescent Probes for the Detection of Amyloid Self-Assembly In Vitro and In Vivo
Current Protein & Peptide Science Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications
Current Medicinal Chemistry Meet the Editorial Board
Current Alzheimer Research Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry Long non-coding RNAs in Alzheimer’s disease
Current Topics in Medicinal Chemistry Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer’s Disease
Current Alzheimer Research Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy Natural AD-Like Neuropathology in Octodon degus: Impaired Burrowing and Neuroinflammation
Current Alzheimer Research The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical Biotechnology Recent Developments in Cholinesterases Inhibitors for Alzheimers Disease Treatment
Current Medicinal Chemistry Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Current Alzheimer Research